Wilson Sonsini Advises Optum Ventures and Oxford Science Enterprises on Series B Investment in BehaVR
- Client Highlights
- Digital Health
- Life Sciences
On December 13, 2022, virtual reality mental and behavioral health companies BehaVR and OxfordVR announced their merger, supported by an initial $13 million in Series B funding led by Optum Ventures and Oxford Science Enterprises, with participation from Confluent Health, Accenture Ventures, Chrysalis Ventures, and Thornton Capital. Wilson Sonsini Goodrich & Rosati advised lead investors Optum Ventures and Oxford Science Enterprises on the transaction, in collaboration with Taylor Wessing.
The combination of the two digital therapeutic companies creates the largest VR delivery platform for evidence-based digital behavioral therapies and accelerates the combined company’s growth strategy. Operating under the BehaVR brand, the comprehensive VR treatment platform will help providers, payers, and employers deliver and increase access to enhanced behavioral care.
The Wilson Sonsini team that advised Optum Ventures and Oxford Science Enterprises on the transaction included:
Employee Benefits and Compensation
For more information, please see BehaVR’s news release.